BRPI0919844A2 - compostos de azaindazol como antagonistas do receptor ccr1 - Google Patents

compostos de azaindazol como antagonistas do receptor ccr1

Info

Publication number
BRPI0919844A2
BRPI0919844A2 BRPI0919844A BRPI0919844A BRPI0919844A2 BR PI0919844 A2 BRPI0919844 A2 BR PI0919844A2 BR PI0919844 A BRPI0919844 A BR PI0919844A BR PI0919844 A BRPI0919844 A BR PI0919844A BR PI0919844 A2 BRPI0919844 A2 BR PI0919844A2
Authority
BR
Brazil
Prior art keywords
receptor antagonists
ccr1 receptor
azaindazole compounds
azaindazole
compounds
Prior art date
Application number
BRPI0919844A
Other languages
English (en)
Portuguese (pt)
Inventor
David Swinamer Alan
Christopher Raudenbush Brian
Nicholas Cook Brian
Mao Can
Harcken Christian
Kuzmich Daniel
Robert Fandrick Daniel
Disalvo Darren
Razavi Hossein
J Song Jinhua
Neu Jochen
Lord John
Timothy Reeves Jonathan
Liu Pingrong
Wai-Ho Lee Thomas
Tan Zhulin
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0919844A2 publication Critical patent/BRPI0919844A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0919844A 2008-09-26 2009-09-22 compostos de azaindazol como antagonistas do receptor ccr1 BRPI0919844A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10040108P 2008-09-26 2008-09-26
PCT/US2009/057778 WO2010036632A1 (en) 2008-09-26 2009-09-22 Azaindazole compounds as ccr1 receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0919844A2 true BRPI0919844A2 (pt) 2019-09-24

Family

ID=41349302

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919844A BRPI0919844A2 (pt) 2008-09-26 2009-09-22 compostos de azaindazol como antagonistas do receptor ccr1

Country Status (24)

Country Link
US (4) US7879873B2 (enExample)
EP (1) EP2346868B1 (enExample)
JP (1) JP5507567B2 (enExample)
KR (1) KR20110060904A (enExample)
CN (1) CN102227425A (enExample)
AP (1) AP2739A (enExample)
AR (1) AR073689A1 (enExample)
AU (1) AU2009296839A1 (enExample)
BR (1) BRPI0919844A2 (enExample)
CA (1) CA2737472A1 (enExample)
CL (1) CL2011000668A1 (enExample)
CO (1) CO6351735A2 (enExample)
EA (1) EA201100524A1 (enExample)
EC (1) ECSP11010932A (enExample)
IL (1) IL210857A0 (enExample)
MA (1) MA32655B1 (enExample)
MX (1) MX2011002951A (enExample)
NZ (1) NZ591115A (enExample)
PE (1) PE20110854A1 (enExample)
TW (1) TW201018683A (enExample)
UA (1) UA103634C2 (enExample)
UY (1) UY32140A (enExample)
WO (1) WO2010036632A1 (enExample)
ZA (1) ZA201100625B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722923C (en) 2008-04-29 2016-08-02 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
JP5411927B2 (ja) * 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
US7879873B2 (en) 2008-09-26 2011-02-01 Boehringer Ingelheim International Gmbh Azaindazole compounds as CCR1 receptor antagonists
PE20120506A1 (es) * 2009-03-19 2012-05-14 Medical Res Council Technology Derivados de pirazolopiridina como inhibidores de quinasas
SI2491028T1 (sl) 2009-10-21 2014-03-31 Boehringer Ingelheim International Gmbh Indazolne in pirazolopiridinske spojine kot antagonisti receptorja CCR1
EP2493875B1 (en) * 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Heterocyclic compounds as ccr1 receptor antagonists
IN2012DN05081A (enExample) * 2009-12-08 2015-10-09 Boehringer Ingelheim Int
EP2563787B1 (en) * 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Azaindazole amide compounds as ccr1 receptor antagonists
EP2388260A1 (de) * 2010-05-21 2011-11-23 Archimica GmbH Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors
CN103384668B (zh) 2010-09-03 2017-05-31 福马Tm有限责任公司 用于抑制nampt的化合物和组合物
US8546442B2 (en) 2010-12-23 2013-10-01 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as CCR1 receptor antagonists
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
CN102775365A (zh) * 2011-05-10 2012-11-14 无锡立诺康医药科技有限公司 5-氨基取代基-异噁唑类化合物或其酸式盐的合成工艺
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
WO2013062945A1 (en) 2011-10-24 2013-05-02 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2013060865A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2820017B1 (en) * 2012-03-02 2016-12-21 Genentech, Inc. Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
AR091858A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
US9045477B2 (en) * 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2970306A4 (en) * 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
FR3016879A1 (fr) * 2014-01-29 2015-07-31 Guillaume Laconde Procede de preparation de benzotriazole n-acyles
ES2674240T3 (es) 2014-03-17 2018-06-28 Pfizer Inc. Inhibidores de diacilglicerol aciltransferasa 2 para su uso en el tratamiento de trastornos metabólicos y relacionados
NZ723530A (en) 2014-04-14 2023-05-26 Boehringer Ingelheim Int Compounds as modulators of ror gamma
JP6810988B2 (ja) 2015-10-23 2021-01-13 ヴィフォール （インターナショナル） アクチェンゲゼルシャフトＶｉｆｏｒ （Ｉｎｔｅｒｎａｔｉｏｎａｌ） ＡＧ 新規なフェロポーチン阻害剤
EP3373732A1 (en) 2015-11-13 2018-09-19 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017081312A1 (en) 2015-11-13 2017-05-18 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
JP6997095B2 (ja) 2016-03-07 2022-02-03 ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド 抗菌性化合物およびその使用
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
TWI853814B (zh) 2018-05-31 2024-09-01 南韓商Ｃ＆Ｃ新藥研究所 雜環衍生物及其用途
CN111393376B (zh) * 2020-05-11 2022-05-13 安徽赛迪生物科技有限公司 一种2-氯嘧啶-4-甲酸的合成方法
WO2021262878A1 (en) * 2020-06-24 2021-12-30 Oregon Health & Science University Novel molecule for modulation of innate immune responses controlled by sting protein

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242931A (en) 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
US4999363A (en) 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
CA2195129C (en) 1991-03-28 2002-09-10 Anabella Villalobos Substituted piperidine intermediates for producing heterocyclic-cyclic amine derivatives capable of inhibiting cholinesterase
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
BR9305569A (pt) 1992-07-03 1995-12-26 Kumiai Chemical Industry Co Derivados heterocíclicos condensados e herbicidas
US5534481A (en) 1993-06-25 1996-07-09 Kumiai Chemical Industry Co., Ltd. Indazolesulfonylurea derivative, its use and intermediate for its production
JPH10509721A (ja) 1994-12-06 1998-09-22 メルク シヤープ エンド ドーム リミテツド ５ｈｔ１レセプターアゴニストとしてのアゼチジン、ピロリジン及びピペリジン誘導体
GB9519563D0 (en) 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
AU1345697A (en) 1995-12-22 1997-07-17 Du Pont Merck Pharmaceutical Company, The Novel integrin receptor antagonists
JPH101478A (ja) 1996-06-11 1998-01-06 Kumiai Chem Ind Co Ltd インダゾールスルホニル尿素誘導体及び除草剤
GB9615449D0 (en) 1996-07-23 1996-09-04 Merck Sharp & Dohme Therapeutic agents
IL135714A0 (en) 1997-11-04 2001-05-20 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
ES2248084T3 (es) 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
WO2000076970A2 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
WO2001000656A2 (en) 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
GB0030304D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030305D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7058826B2 (en) * 2000-09-27 2006-06-06 Amphus, Inc. System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment
US20020052373A1 (en) 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
US7223782B2 (en) 2001-11-01 2007-05-29 Icagen, Inc. Pyrazole-amides and -sulfonamides
US20090286791A1 (en) 2001-11-27 2009-11-19 Takeda Pharmaceutical Company Limited Amide Compounds
WO2003053941A2 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
EP1497278B1 (en) 2002-04-11 2010-05-26 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic amide derivatives as cytokine inhibitors
AU2003241925A1 (en) 2002-05-31 2003-12-19 Eisai R&D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
DE60328690D1 (de) * 2002-06-12 2009-09-17 Chemocentryx Inc 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0203825D0 (sv) 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
US7371757B2 (en) 2003-08-15 2008-05-13 Astrazeneca Ab Fused heterocycles as inhibitors of glutamate racemase(MURI)
AU2006216917A1 (en) 2005-02-24 2006-08-31 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
GB0504828D0 (en) * 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
PT1881823E (pt) 2005-05-17 2015-03-02 Sarcode Bioscience Inc Composições e métodos para o tratamento de transtornos oculares
EA017278B9 (ru) * 2005-06-22 2013-01-30 Кемосентрикс, Инк. Соединения азаиндазола и способы применения
DK1924561T3 (da) 2005-09-01 2012-12-10 Lilly Co Eli 6-arylalkylamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiner as 5-ht2c-receptor agonister
US20080262040A1 (en) 2005-10-25 2008-10-23 Smithkline Beecham Corporation Chemical Compounds
TW200829578A (en) * 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
CN101743242A (zh) * 2007-06-29 2010-06-16 苏尼西斯制药有限公司 用作raf激酶抑制剂的杂环化合物
WO2009037570A2 (en) 2007-08-10 2009-03-26 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009085256A1 (en) * 2007-12-27 2009-07-09 Panacos Pharmaceuticals, Inc. Anti-hiv compounds
CA2722923C (en) 2008-04-29 2016-08-02 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
JP5411927B2 (ja) 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
US7879873B2 (en) 2008-09-26 2011-02-01 Boehringer Ingelheim International Gmbh Azaindazole compounds as CCR1 receptor antagonists
SI2491028T1 (sl) 2009-10-21 2014-03-31 Boehringer Ingelheim International Gmbh Indazolne in pirazolopiridinske spojine kot antagonisti receptorja CCR1
EP2493875B1 (en) 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Heterocyclic compounds as ccr1 receptor antagonists
IN2012DN05081A (enExample) * 2009-12-08 2015-10-09 Boehringer Ingelheim Int
EP2563787B1 (en) 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Azaindazole amide compounds as ccr1 receptor antagonists
US8546442B2 (en) 2010-12-23 2013-10-01 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as CCR1 receptor antagonists

Also Published As

Publication number Publication date
AP2739A (en) 2013-09-30
US8163918B2 (en) 2012-04-24
CO6351735A2 (es) 2011-12-20
UY32140A (es) 2010-04-30
EP2346868A1 (en) 2011-07-27
NZ591115A (en) 2012-10-26
IL210857A0 (en) 2011-04-28
KR20110060904A (ko) 2011-06-08
AU2009296839A1 (en) 2010-04-01
MX2011002951A (es) 2011-04-26
ZA201100625B (en) 2011-09-28
US20120136158A1 (en) 2012-05-31
UA103634C2 (en) 2013-11-11
US20110086846A1 (en) 2011-04-14
EP2346868B1 (en) 2016-01-27
AR073689A1 (es) 2010-11-24
EA201100524A1 (ru) 2011-10-31
US20120035370A1 (en) 2012-02-09
TW201018683A (en) 2010-05-16
US8063065B2 (en) 2011-11-22
MA32655B1 (fr) 2011-09-01
JP2012503664A (ja) 2012-02-09
JP5507567B2 (ja) 2014-05-28
ECSP11010932A (es) 2011-04-29
PE20110854A1 (es) 2011-12-23
US8338610B2 (en) 2012-12-25
WO2010036632A1 (en) 2010-04-01
US20100093724A1 (en) 2010-04-15
CA2737472A1 (en) 2010-04-01
AP2011005685A0 (en) 2011-04-30
CN102227425A (zh) 2011-10-26
US7879873B2 (en) 2011-02-01
CL2011000668A1 (es) 2011-10-28

Similar Documents

Publication Publication Date Title
BRPI0919844A2 (pt) compostos de azaindazol como antagonistas do receptor ccr1
BRPI0909157A2 (pt) compostos heterocíclicos como antagonistas de receptores de adenosina
BRPI0810462A2 (pt) Derivados de quinolina-carboxamida como antagonistas de p2y12
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI1013821A2 (pt) piridinas substituídas como antagonistas de ccr3.
BRPI0717023A2 (pt) Tiazol pirazolopirimidina como antagonistas do receptor de crf1
BRPI1016189A2 (pt) compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
BRPI0911542A2 (pt) compostos de quinuclina como ligantes de receptor de receptor de acetilcolina alfa-7-nicotínica
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
BRPI0811065A2 (pt) Indazóis 5-heteroaril substituídos como inibidores de quinase
IL225978A0 (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
DK2501703T3 (da) Spiropiperidinforbindelser som orl-1-receptorantagonister
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
BRPI0817245A2 (pt) Derivados e quinolina como antagonistas receptores de 5ht5a
DK2501704T3 (da) Spiropiperidinforbindelser som oral-1-receptorantagonister
BRPI0912475A2 (pt) compostos como inibidores de quinase
BRPI0817061A2 (pt) Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3
BRPI0814806A2 (pt) Pirazinas substituídas como antagonistas de cb1
BRPI0815674A2 (pt) Aril-éter de pirrolidina como antagonista de receptor de nk3
BRPI0814767A2 (pt) Derivados de monoamida como antagonistas do receptor de orexina
BRPI0720078A2 (pt) 2-aminoquinolinas como antagonistas de receptores de 5-ht(5a)
BRPI0914936A2 (pt) naftiridininonas como inibidores de aurora quinase
BRPI0915834A2 (pt) 6-(1-piperazinil)-piridazinas substituídas como antagonistas do receptor de 5-ht6
BRPI0822693A2 (pt) Derivados de quinuclidina como antagonistas do receptor muscarínico m3

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.